Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 20/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.54 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6023842 | 0.96 | EGFR (0.93) | EGFRERBB2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL466103 | 0.92 | EGFR (0.84) | EGFRERBB2ERBB4 | |
| SCHEMBL6023986 | 0.91 | EGFR (0.83) | EGFRERBB2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL1728567 | 0.91 | EGFR (0.83) | EGFRERBB2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL6527950 | 0.91 | EGFR (0.83) | EGFRERBB2ERBB4 | |
| SCHEMBL1730909 | 0.91 | EGFR (0.83) | EGFRERBB2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL1730936 | 0.90 | EGFR (0.82) | EGFRERBB2 | |
| SCHEMBL1730413 | 0.90 | EGFR (0.82) | EGFRERBB2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL1728778 | 0.90 | EGFR (0.81) | EGFRERBB2 | |
| SCHEMBL1730873 | 0.90 | EGFR (0.81) | EGFRERBB2CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1569937-B1 | C-6 MODIFIED INDAZOLYLPYRROLOTRIAZINES | BRISTOL MYERS SQUIBB CO (US) | 2011-11-23 | — | — | EP | disclosed |
| US-7148220-B2 | C-6 modified indazolylpyrrolotriazines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-12 | — | — | US | disclosed |
| US-20050222153-A1 | C-6 modified indazolylpyrrolotriazines | VITE GREGORY D | 2005-10-06 | — | — | US | disclosed |
| US-6916815-B2 | C-6 modified indazolylpyrrolotriazines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222153-A1 | C-6 modified indazolylpyrrolotriazines | ERBB2, ERBB4, EGFR | EGFR 3/4885ERBB2 1/4885CYP3A4 1464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.